130 related articles for article (PubMed ID: 8051623)
1. Antibody and cellular responses after HIV immunization.
Wahren B
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 8051623
[No Abstract] [Full Text] [Related]
2. Cellular immune response to HIV gp160 vaccine.
Stricker RB; Goldberg B
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 7914236
[No Abstract] [Full Text] [Related]
3. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
[TBL] [Abstract][Full Text] [Related]
5. Current progress in HIV vaccines.
Westblom TU; Belshe RB; Gorse GJ
Mo Med; 1991 Nov; 88(11):762-5. PubMed ID: 1805131
[No Abstract] [Full Text] [Related]
6. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.
Akerblom L; Nara P; Dunlop N; Morein B
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
Graham BS
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
[No Abstract] [Full Text] [Related]
8. Human trials of AIDS vaccines: current status and future directions.
Koff WC; Fauci AS
AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
[No Abstract] [Full Text] [Related]
9. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation.
Wang B; Boyer J; Srikantan V; Ugen K; Gilbert L; Phan C; Dang K; Merva M; Agadjanyan MG; Newman M
Virology; 1995 Aug; 211(1):102-12. PubMed ID: 7645204
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
11. Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160.
Vasudevachari MB; Uffelman KW; Kovacs J; Yeh CK; Lane HC; Salzman NP
J Acquir Immune Defic Syndr (1988); 1992; 5(8):817-21. PubMed ID: 1517967
[TBL] [Abstract][Full Text] [Related]
12. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
13. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
[TBL] [Abstract][Full Text] [Related]
14. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
Wahren B; Bratt G; Persson C; Levén B; Hinkula J; Gilljam G; Nordlund S; Eriksson L; Volvovitz F; Broliden PA
J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):220-9. PubMed ID: 7906300
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.
McElrath MJ; Corey L; Greenberg PD; Matthews TJ; Montefiori DC; Rowen L; Hood L; Mullins JI
Proc Natl Acad Sci U S A; 1996 Apr; 93(9):3972-7. PubMed ID: 8633000
[TBL] [Abstract][Full Text] [Related]
16. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting.
McElrath MJ; Corey L; Berger D; Hoffman MC; Klucking S; Dragavon J; Peterson E; Greenberg PD
J Infect Dis; 1994 Jan; 169(1):41-7. PubMed ID: 8277196
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
18. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with gp160 in HIV.
Oyaizu N; Chirmule N; Pahwa S
N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
